A review on basics of pharmaceutical antiviral drug

Akshay Gaikwad*, Prashant Naiknavare, Vishal Kulkarani, Aishwarya sarvade, R R Bendgude

Shri Ganpati Institute of Pharmaceutical Sciences and Research, Maharashtra, India

Refer this article

Akshay Gaikwad, Prashant Naiknavare, Vishal Kulkarani, Aishwarya sarvade, R R Bendgude, A review on Basics of Pharmaceutical Antiviral Drug. May-June 2025, V3 – I3, Pages - 07 – 10. Doi: https://doi.org/10.55522/ijti.v3i3.0069.

ABSTRACT

Eleven drugs approved by the food and drug administration for the treatment of viral infections (other than those caused by human immunodeficiency virus type-1 {HIV-1} or those complicating such infection) will be reviewed in this article. Antiviral drug design could, in principle, be targated at either viral proteins or cellular proteins. The first approach is likely to yield more specific, less toxic compound, with ta narrow spectrum of antiviral activity and a higher likelihood of virus drug-resistance development.challenges.

Keywords:

Antiviral agent, antiviral drug MOA (mechanism of action), Strategies in the design of antiviral drugs.